Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SURFING: Ranibizumab vs Triamcinolone for Uveitic Macular Edema
NCT00846625Phase 2Withdrawn
- Sponsor
- University of Utah
- Start
- Nov 2009
- Primary completion
- Aug 2011
- Modality
- Antibody Fragments, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of ranibizumab in uveitic macular edema (UME), sponsored by University of Utah. Primary endpoint: Ocular adverse events at 12 months. Planned start Nov 2009; status: withdrawn.
02
Drugs
ranibizumab
03
Conditions
uveitic macular edema (UME)
Beyond the preview
Go deeper on NCT00846625.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00846625.